IIM
ALXN

Ipswich Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Ipswich Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-250
Closed -$24K – 426
2018
Q4 		$24K Buy
+250
New +$29.6K 0.01% 319
2016
Q2 		– Sell
-350
Closed -$50K – 351
2016
Q1 		$50K Buy
+350
New +$51.4K 0.02% 229

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ipswich Investment Management's ALXN Position: Q1 2019 in Review

Ipswich Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 250 shares — an estimated $24K sold.

Ipswich Investment Management first reported a position in ALXN in Q1 2016 and held it in 2 quarters. The position peaked at $50K in Q1 2016. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • Ipswich Investment Management reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Ipswich Investment Management sold 250 Alexion Pharmaceuticals shares in Q1 2019, an estimated $24K.
  • Ipswich Investment Management first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Ipswich Investment Management's Alexion Pharmaceuticals position peaked at $50K in Q1 2016.
  • 611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Ipswich Investment Management's 13F filing for Q1 2019, filed 12 Apr 2019.